Skip to main content

Month: May 2020

Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2020

VD kommenterarIBT utvecklar läkemedelskandidaten IBP-9414 för att minska förekomsten av nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda barn. Möjligheten att inkludera två indikationsområden för IBP-9414 kan öka chanserna till framgång i den pågående fas III-studien, ”The Connection Study”, och därmed produktens framtida marknadspotential. IBP-9414 innehåller Lactobacillus reuteri som aktiv substans, vilket är en human bakteriestam som återfinns naturligt i bröstmjölk. Detta VD-ord författas i början av maj 2020 under en pågående COVID-19-pandemi.Vi ser att det blir svårare att upprätthålla full aktivitet hos våra leverantörer och att ett flertal sjukhus påverkas i större grad desto längre tid pandemin pågår. Vår studie är inte beroende av “normala” “sjukhus- eller...

Continue reading

SBQ Holdings, LLC, a MasterBeat Corp. Subsidiary, Announces JTEC Automotive will Build High Performance 69 Pontiac Firebird

MIRAMAR BEACH, FL, May 11, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ MasterBeat Corporation (OTC: MSTO), a company specializing in hard, tangible asset acquisitions with an intense focus on real estate, precious metals, collectible classic automobiles, and other tangible assets through its subsidiary SBQ Holdings, LLC, is pleased to announce its automotive division JTEC Automotive Inc has entered into a partnership agreement to complete the restoration and customization of a 1969 Pontiac Firebird 455 Big Block.JTEC Automotive Inc. and Boosted Autos LLC. will complete the building and restoration of a 1969 Pontiac Firebird. This Firebird sports a 455 cubic inch H.O.(high output) engine that has been machined and professionally built into a high performance 469 cubic inch engine with a Hydraulic Cam, from Competition Cams ( Intake:...

Continue reading

13 Sophos Executives Named 2020 CRN Women of the Channel

BURLINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) — Sophos (LSE: SOPH), a global leader in next-generation cybersecurity, today announced that CRN®, a brand of The Channel Company, has named 13 Sophos executives to its 2020 Women of the Channel list. For the fourth consecutive year, Sophos has the most women from any dedicated IT security company honored on the esteemed list and acclaimed for their unique strengths, vision and channel contributions.Sophos executives recognized on the CRN list, which is comprised of women from all areas of the IT ecosystem, including technology vendors, distributors, solution providers, and other IT organizations, include:Kendra Krause, senior vice president, global channels and sales operationsJustine Lewis, vice president, worldwide regional and channel marketingErin Malone, vice president, North...

Continue reading

Vanstar Announces Grant of Stock Options

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES.MONTREAL, May 11, 2020 (GLOBE NEWSWIRE) — Vanstar’s management has granted one million common share purchase options to some of its directors and officers. These were granted, as part of its option plan, at a price of $1.12 per share for a maximum term of five years. The TSX Venture Exchange and its regulator (as defined in the TSX Venture Exchange policies) accept no responsibility for the truthfulness or accuracy of its content. 

Continue reading

Vanstar annonce l’octroi d’options sur ses actions

CE COMMUNIQUÉ NE PEUT PAS ÊTRE DISTRIBUÉ AUX SERVICES DE FIL DE PRESSE AMÉRICAINS POUR FINS DE DIFFUSION AUX ÉTATS-UNIS.MONTRÉAL, 11 mai 2020 (GLOBE NEWSWIRE) — La direction de Ressources Minières Vanstar a octroyé 1 million d’options d’achat d’actions ordinaires à certains de ses administrateurs et dirigeants. Celles-ci ont été accordées, dans le cadre de son plan d’options, au prix de 1,12 $ par action pour une durée maximale de cinq ans.La Bourse de croissance TSX ainsi que son fournisseur de services de régulation (tel que ce terme est défini dans les politiques de la bourse de croissance du TSX) n’acceptent aucune responsabilité concernant la véracité ou l’exactitude de son contenu.

Continue reading

HMS to Present at the BofA Securities 2020 Health Care Conference

IRVING, Texas, May 11, 2020 (GLOBE NEWSWIRE) — HMS Holdings Corp.  (Nasdaq: HMSY) today announced its management team is scheduled to participate in the BofA Securities Health Care Conference on Tuesday, May 12, 2020, at 10:20 a.m. ET.Management will deliver an HMS overview presentation and participate in a virtual fireside chat session.  An audio webcast and copy of the presentation will be available on the Company’s website at http://investor.hms.com/events-and-presentations.About HMSHMS advances the healthcare system by helping healthcare organizations reduce costs and improve health outcomes. Through our industry-leading technology, analytics and engagement solutions, we save billions of dollars annually while helping consumers lead healthier lives. HMS provides a broad range of payment accuracy and population health management...

Continue reading

Blood Group Typing Market to Rise at 7.2% CAGR till 2027; Increasing Demand for Efficient and Economical Blood Grouping Technologies to Boost the Market: Fortune Business Insights™

Pune, May 11, 2020 (GLOBE NEWSWIRE) — The global blood group typing market size is projected to reach USD 2.68 billion by 2027, exhibiting a CAGR of 7.2% during the forecast period. Rising prevalence of anemia worldwide is set to fuel the growth of this market, shares Fortune Business Insights™ in its report, titled “Blood Group Typing Market Size, Share & Industry Analysis, By Product (Instruments, and Reagents & Kits), By Test Type (ABO Tests, Antigen Typing, Antibody Screening, Cross-matching Tests, and HLA Typing), By Techniques (Serology Tests, and Molecular Tests), By End User (Hospital-based Laboratories, and Independent Laboratories & Blood Banks), and Regional Forecast, 2020-2027”. World Health Organization (WHO) data reveals that nearly 1.62 billion people, or 24.8% of the global population, are affected...

Continue reading

Ex-day dividend payment of AB Rokiškio sūris

The Ordinary General Meeting of Shareholders of AB Rokiškio sūris (company code 173057512, registered office address Pramonės street 3, Rokiškis) held on 30 April 2020, decided to allocate a dividend of EUR 0.10 per share for 2019 (the total amount allocated for dividends for 2019 is EUR 3.501 million).Dividends will be entitled to those persons who will be shareholders of the Company at the end of the tenth business day after the General Meeting of Shareholders that has decided to allocate a part of the profit for dividend payment (i.e. 15 May 2020).The first day without rights (i.e. Ex-Date), from which the shares of AB Rokiškio sūris (RSU1L, ISIN code LT0000100372) acquired on the stock exchange with settlement cycle T + 2 do not entitle to receive dividends for 2019, is 14 May 2020.Dalius TrumpaCEOTeleph. +370 458 55200

Continue reading

AB „Rokiškio sūris“ dividendų mokėjimo ex-diena

2020 m. balandžio 30 d. įvykęs AB „Rokiškio sūris“ (įmonės kodas 173057512, buveinės adresas Pramonės g.3, Rokiškis) eilinis visuotinis akcininkų susirinkimas už 2019 m. nusprendė skirti 0,10 eurų dividendų vienai akcijai (bendra dividendams skiriama suma už 2019 m. sudaro 3,501 mln. eurų).Dividendus turės teisę gauti tie asmenys, kurie dešimtos darbo dienos pabaigoje po visuotinio akcininkų susirinkimo, priėmusio sprendimą skirti dalį pelno dividendams išmokėti (t.y. 2020 m. gegužės mėn. 15 d.) pabaigoje bus Bendrovės akcininkai.Pirmoji diena be teisių (angl. Ex-Date), nuo kurios vertybinių popierių biržoje su atsiskaitymo ciklu T+2 įsigytos AB „Rokiškio sūris“ (RSU1L,  ISIN kodas LT0000100372) akcijos nesuteikia teisės gauti dividendų už 2019 metus, yra 2020 m. gegužės 14 diena.Dalius TrumpaDirektoriusTel. +370 458 55200

Continue reading

PAVmed to Hold Business Update Conference Call on May 21, 2020

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May 21, 2020 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss first quarter 2020 financial results.To access the conference call, U.S.-based listeners should dial (877) 407-3982 and international listeners should dial (201) 493-6780. All listeners should provide the operator with the conference call name “PAVmed,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.